HMA decitabine-induced GLI3R re-expression resulted in decreased GLI1 expression levels in AML cell lines and increased their sensitivity to the SMO inhibitor glasdegib, thereby reducing AML cell viability and proliferation (Chaudhry et al., 2017). This evidence concerns the gene GLI1 and acute myeloid leukemia.